Published in J Thorac Oncol on March 01, 2006
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst (2007) 1.52
Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2. Mol Cancer (2017) 1.43
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol (2008) 1.41
Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw (2008) 1.18
Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res (2011) 1.10
Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp Pathol (2013) 1.04
Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting. Radiol Oncol (2012) 0.89
Adhesion of small cell lung cancer cells to E- and P-selectin under physiological flow conditions: implications for metastasis formation. Histochem Cell Biol (2011) 0.86
Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials. J Carcinog (2011) 0.85
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol (2010) 0.83
The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer. Radiat Oncol (2011) 0.83
Expression of focal adhesion kinase in small-cell lung carcinoma. Cancer (2011) 0.83
The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis. Onco Targets Ther (2013) 0.83
The antitumor activity study of ginsenosides and metabolites in lung cancer cell. Am J Transl Res (2016) 0.81
Mosquito coil exposure associated with small cell lung cancer: A report of three cases. Oncol Lett (2015) 0.80
Increased Expression of Eps15 Homology Domain 1 is Associated with Poor Prognosis in Resected Small Cell Lung Cancer. J Cancer (2015) 0.80
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer (2007) 0.78
Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC? J Cancer (2015) 0.78
Novel oncolytic viral therapies in patients with thoracic malignancies. Oncolytic Virother (2016) 0.78
Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC). Int J Clin Exp Pathol (2015) 0.77
Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase. Onco Targets Ther (2016) 0.76
Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer. Drug Des Devel Ther (2013) 0.75
Enlightening discriminative network functional modules behind Principal Component Analysis separation in differential-omic science studies. Sci Rep (2017) 0.75
24-Methyl-Cholesta-5,24(28)-Diene-3β,19-diol-7β-Monoacetate Inhibits Human Small Cell Lung Cancer Growth In Vitro and In Vivo via Apoptosis Induction. Mar Drugs (2017) 0.75
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol (2003) 6.66
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002. J Natl Cancer Inst (2003) 2.99
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol (2002) 2.07
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys (2004) 1.83
National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr (2004) 1.70
Creeping phase II-ism and the medical pharmaceutical complex: weapons of mass distraction in the war against lung cancer. J Clin Oncol (2005) 1.39
Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis. J Thorac Oncol (2006) 1.38
Small cell lung cancer: state of the art and future perspectives. Lung Cancer (2004) 1.37
Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn (2003) 1.20
Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.13
Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol (2009) 1.10
Outcome of radiation therapy for renal transplant rejection refractory to chemical immunosuppression. Radiother Oncol (2005) 0.91
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol (2010) 0.91
Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol (2002) 0.87
Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer. Oncologist (2003) 0.85
Locally advanced esophageal cancer. Curr Treat Options Oncol (2002) 0.84
Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 0.80
Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer (2002) 0.80
Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003. Am J Clin Oncol (2003) 0.76
Recall those thrilling days of yesteryear ... Oncologist (2010) 0.75
The thrill of victory; the agony of defeat. Int J Radiat Oncol Biol Phys (2008) 0.75
Limited-disease small-cell lung cancer research: sense and nonsense. Int J Radiat Oncol Biol Phys (2004) 0.75